Cytotoxic Activity of Metal Complexes of Biogenic Polyamines:  Polynuclear Platinum(II) Chelates by Teixeira, Luísa J. et al.
Cytotoxic Activity of Metal Complexes of Biogenic Polyamines: Polynuclear
Platinum(II) Chelates
Luı´sa J. Teixeira,| Marta Seabra,| Elisa Reis,| M. Teresa Gira˜o da Cruz,#,† M. Conceicü a˜o Pedroso de Lima,#,†
Eula´lia Pereira,§ M. Adelaide Miranda,‡ and M. Paula M. Marques*,|,#
Research Unit “Molecular Physical-Chemistry” and Biochemistry Department, Faculty of Sciences and Technology, University
of Coimbra, 3001-401 Coimbra, Portugal, Centre for Neuroscience and Cellular Biology, University of Coimbra,
3000 Coimbra, Portugal, and REQUIMTE/Chemistry Department and ICETA/Chemistry Department, Faculty of Sciences,
University of Porto, 4169-007 Porto, Portugal
Received December 4, 2003
Several polynuclear Pt(II) chelates with biogenic polyamines were synthesized and screened
for their potential antiproliferative and cytotoxic activity in different human cancer cell lines.
To gather information regarding the structure-activity relationships underlying their biological
activity, the complexes studied were designed to differ in geometrical parameters such as the
nature of the ligand and the number and chemical environment of the metal centers. Distinct
effects were found for different cell lines and different structural characteristics of the complexes;
chelates II, III, and IV displayed specificity toward the HeLa and HSC-3 epithelial-type cells,
while V, VI, and VII were clearly more effective against the THP-1, MOLT-3, and CCRF-
CEM leukemia cell lines. The toxicity of these Pt(II) complexes on noncancer cells was, in all
cases, found to be reversed upon drug removal.
Introduction
Platinum-based antitumor drugs have been the target
of intense research since Rosenberg’s discovery of an
unexpected inhibition of cell division by platinum
complexes in the late 1960s.1 It is presently well-known
that the antitumor properties of these kinds of com-
pounds are based on a selective interaction with DNA
inside the cells. Despite its well-established anticancer
properties, cisplatin (cis-diaminedichloroplatinum(II),
CDDP), one of the most widely used anticancer drugs,
presents several drawbacks, namely, severe toxicity and
development of resistance in certain types of cancer
cells.2 Therefore, the search for structurally novel
platinum compounds displaying antitumor activity is
crucial, aiming at the design of more efficient, less toxic
drugs (by avoiding undesired reactions within the cell)
that are non-cross-resistant with first- and second-
generation agents such as cisplatin and carboplatin (cis-
diamine(cyclobutane-1,1-dicarboxylato)platinum(II)).
Multinuclear Pt(II) complexes, containing two or three
cisplatin-like metal centers and variable length biogenic
polyamines as bridging linkers, constitute a new class
of platinum-based, third-generation drugs of great
potential clinical importance. These compounds, which
have been the subject of intense study for the past few
years,3-22 were found to be distinct from their mono-
nuclear counterparts in terms of DNA binding features,
yielding adducts containing “long-distance” intra- and
interstrand cross-links not available to the conventional
mononuclear platinum complexes.9,23 Moreover, these
polynuclear metal complexes have often been reported
to overcome acquired cisplatin resistance24-27 probably
because of a distinct mechanism of DNA interaction that
results in different types of drug-induced DNA lesions.
The presence of more than one metal center in these
Pt(II) multifunctional chelates is thus expected to lead
to a higher efficacy and specificity regarding DNA
binding (e.g., increased number of interstrand cross-
links,28 possibly at more than one position). In addition,
each type of polynuclear platinum structure (e.g., num-
ber and nature of the leaving groups and their geometry
relative to the bridging amines) has been shown, in
recent studies, to have its own particular cytotoxic
characteristics (e.g., triplatinum BBR3464, currently in
phase III of clinical trials16,17,19,29,30). In fact, it is known
that a simple chemical modification in the structure of
a certain compound may alter its DNA binding proper-
ties and/or the relative amounts of interstrand cross-
links in double-stranded DNA, thus governing its
antiproliferative and cytotoxic activity. It should then
be possible to functionalize DNA-binding modes to
obtain compounds displaying not only selective but also
enhanced and unique anticancer properties.
The present work aims at screening for potential
antiproliferative and cytotoxic activities of several di-
and trinuclear Pt(II) complexes in different types of
human cancer cells (leukemia and epithelial-like adher-
ent cell lines), following a previous study on similar
systems.31 These chelates, containing the biogenic
polyamines spermidine (H2N(CH2)3NH(CH2)4NH2) and
spermine (H2N(CH2)3NH(CH2)4NH(CH2)3NH2) as bridg-
ing linkers, differ in the metal coordination pattern, as
well as in the number and geometry of their leaving
groups. This is intended as an interactive structure-
activity research work, the structural characteristics of
the compounds tested (determined in a concurrent study
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through physical-chemical methods32-36) being changed
according to their antitumor activity evaluation. Thus,
the results obtained from these studies may hopefully
contribute to a better understanding of the molecular
basis of toxicity (i.e., of the biochemical processes
underlying the antiproliferative effect of these kinds of
compounds), which is fundamental in order to design
new cytostatic agents with improved therapeutical
properties.
Results and Discussion
The distinct complexes tested for their antitumor
activity differ mainly in the number and chemical
environment of the Pt(II) centers (number and geometry
of the leaving groups), as well as in the nature and
coordination mode of the amine linkers (Figure 1). The
flexibility, charge, and hydrogen-bonding capabilities of
these kinds of compounds determine their interaction
with DNA. The present results may be interpreted as
reflecting these structure-activity relationships, al-
though they do not constitute direct evidence of a drug-
DNA interaction. It should be emphasized that, apart
from covalent bonding to the DNA double helix, both
electrostatic interactions and formation of hydrogen
bonds37 play a very important role in the mechanism of
interaction of these kinds of cationic polyamine metal
complexes with DNA, which determines their antipro-
liferative and cytotoxic action. According to Cleare and
Hoeschele’s structure-activity relationships (SARs) for
platinum(II) complexes,38,39 for such compounds to
display significant antitumor activity they should have
a cis geometry with the general formula cis-[PtX2(Am)2],
Am being an inert amine containing at least one NH
moiety and X being an anionic leaving group with a
weaker trans effect than the amine. All the complexes
reported in the present work comply with these condi-
tions except for the number of X groups (which is, in
some of the chelates studied, only 1). However, it should
be noted that conformity to these SAR rules is not
essential for cytostatic activity to occur, since it was
recently found that novel trans-dichloroplatinum(II)
complexes also exhibit significative antitumor activity.40
Among the complexes presently studied, both II and
IV are dinuclear 2,2/c,c Pt(II) chelates;24 i.e., they
comprise two difunctional moieties at each metal center,
in a cis position relative to the bridging ligand(s).
However, while II has two distinct polyamine (spermi-
dine) molecules, each one coordinated to a different
platinum ion, IV contains only one tetraamine ligand
(spermine) acting as a linker for both metal centers,
yielding two identical six-membered intramolecular
rings in a trans orientation relative to each other
(Figure 1). Compound III, in turn, is a trinuclear (2,2,2/
c,c,c) chelate containing (as in species II) two spermidine
units as ligands. However, while in complex II these
molecules act as bidentate N,N′-donor ligands, yielding
two six-membered rings through coordination to each
of the two metal ions, in III all three polyamine nitrogen
atoms coordinate to the three platinum(II) centers,
which may somewhat affect the motional freedom of the
whole compound. Thus, although both II and III are
difunctional relative to each Pt(II), the former has two
cisplatin-like structures (PtCl2(NHn)2) (n ) 1 or 2), as
opposed to III which has three, yielding (upon hydroly-
sis) respectively four and six possible coordination sites
to the DNA helix. Furthermore, the terminal protonated
Figure 1. Schematic representation of the polynuclear polyamine Pt(II) complexes studied in this work.28
2918 Journal of Medicinal Chemistry, 2004, Vol. 47, No. 11 Teixeira et al.
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(cationic) amino groups of the spermidine linkers in II
are free to eventually interact electrostatically with
DNA. Compound III, in turn, displays a longer, stretched
geometry, which may also be favorable for interacting
with the DNA backbone. As for complexes V, VI, and
VII, they share a particular conformational feature that
renders them quite rigid; they comprise two identical
units, where the metal center coordinates to all three
nitrogen atoms of the bridging spermidine-like amine,
resulting in a nearly cyclic structure defining two
intramolecular rings whose dimensions are determined
by the length of the -N-(CH2)n-N- moieties of the
polyamine linker.
From the dose- and/or time-response curves (cell
density and viability variation as a function of the
incubation time with the drug) plotted for the distinct
complexes and cell lines studied (for different drug
concentrations), it is possible to relate the conforma-
tional preferences of these compounds to their antitumor
activity and to learn from factors such as reversibility
and specificity of their growth-inhibition and/or cytotoxic
effect. The clinically used drug cisplatin was considered
for comparison purposes in all the experiments carried
out in this work except in the case of the HCS-3 cells,
for which carboplatin was used, since it is the most
suitable chemotherapy agent for this particular line.
The results obtained through both the MTT and the
Alamar blue methods were found to be in very good
agreement, as well as to sustain the conclusions yielded
by the Trypan blue assays.
Figures 2 and 3 display the time-dependent antipro-
liferative and cytotoxic effects, respectively, of the
distinct Pt(II) complexes studied (at 100 íM) toward all
the cells tested, both cancer cells and fibroblasts. In
Figure 2. Time dependence of the antiproliferative effect of compounds I-VII (100 íM) toward all the cell lines tested. Cells
(3.0  105 cells/mL) were incubated with the drugs for periods of 24-72 h. Every 24 h, aliquots of the cell suspensions were
removed and the cell density was evaluated by the Trypan blue exclusion method (as described in the Experimental Section). In
addition, the drug was removed 72 h after seeding and the cell density was assessed following a further incubation of 72 h. The
data represent the average ( mean standard deviation from experiments carried out in triplicate: (A) HeLa; (B) HSC-3; (C)
THP-1; (D) MOLT-3; (E) CCRF-CEM; (F) L-132. For intergroup comparison between the different compounds, p < 0.05. For
intergroup comparison between cell lines, the asterisk (/) indicates p < 0.01. Values for cisplatin (CDDP) and carboplatin (CBP)
are included for comparison. Cell densities for the control are as follows: 24 h, 6.7  105 cells/mL; 48 , 9.8  105 cells/mL; 72 h,
15.4  105 cells/mL; 144 h, 25  105 cells/mL).
Polynuclear Pt(II) Chelates Journal of Medicinal Chemistry, 2004, Vol. 47, No. 11 2919
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general, it was verified that chelates IV-VII were
particularly effective against leukemia cells MOLT-3
and THP-1, while the trinuclear complex III displayed
a rather high antiproliferative and cytotoxic activity
toward the epithelial-like lines HeLa and (to a smaller
extent) HSC-3. Thus, a selectivity of action was ob-
served, related to the conformational characteristics of
the compounds studied versus the kind of cancer cells
tested; the cyclic-like, more rigid chelates displayed a
clear preference for leukemia, as opposed to the linear,
cis-oriented, flexible complexes. Concerning the results
on fibroblasts, all the complexes studied displayed a
reversible effect and consequently a rather low toxicity.
Table 1 comprises the values of 50% inhibitory
concentration (concentration of drug yielding a 50%
decrease in either cell density or cell viability, IC50)
measured for the distinct complexes investigated. Com-
Figure 3. Time dependence of the cytotoxic effect of compounds I-VII (100 íM) toward all the cell lines tested. Cells (3  105
cells/mL) were incubated with the drugs for periods of 24-72 h. Every 24 h, aliquots of the cell suspensions were removed and
the cell viability was evaluated by the MTT colorimetric assay (as described in the Experimental Section). In addition, the drug
was removed 72 h after seeding and the cell viability was assessed following a further incubation of 72 h. The data are expressed
as a percentage of the control MTT reduction (100%) and represent the average ( mean standard deviation from experiments
carried out in triplicate: (A) HeLa; (B) HSC-3; (C) THP-1; (D) MOLT-3; (E) CCRF-CEM; (F) L-132. For intergroup comparison
between the different compounds, p < 0.05. For intergroup comparison between cell lines, the asterisk (/) indicates p < 0.01.
Values for cisplatin (CDDP) and carboplatin (CBP) are included for comparison.
Table 1. Cytotoxic Potency (IC50, íM) of the Pt(II) Complexes
I-VII on the Different Cell Lines Testeda
cell line
complex HeLa HSC-3 THP-1 MOLT-3 CCRF-CEM L-132
I 20.0b 96.0 130.0 128.0 125.0 100.0
II 13.0 (13.0b) 20.0 97.0 90.0 83.0 104.0
III 5.0 (5.0b) 11.0 30.0 50.0 78.0 120.0
IV 15.0 20.0 35.0 37.0 30.0 145.0
V 45.0 10.0 6.0 50.0
VI 137.0 12.0 15.0 83.0
VII 62.00 14.0 18.0 135.0
cisplatin 2.0 7.0 2.0 4.0 1.0 2.0
carboplatin 3.0
a Only the values corresponding to an irreversible cytotoxic
effect are presented. IC50 values were calculated from dose-
response curves for a 72 h drug exposure. Data were obtained
through independent measurements of cell density and cell
viability by both the Trypan blue method and the MTT and Alamar
blue assays. b From ref 31.
2920 Journal of Medicinal Chemistry, 2004, Vol. 47, No. 11 Teixeira et al.
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8
pound I displayed little or no effect on either cell growth
or viability for any of the cancer cell lines presently
tested, yielding IC50 values close to or higher than 100
íM, except for the HeLa cells for which a 20 íM value
was measured. As previously reported,31 the ionic
nature of this compound (Figure 1) is probably repon-
sible for its very low antitumor activity. The experi-
ments performed with compounds III and IV on the
monolayer cultures (HeLa and HSC-3) in turn showed
that the former behaves as a very efficient antitumor
drug in these cancer cells, with IC50 values of 5 and 11
íM, respectively. Although less effective, IV also dis-
played antiproliferative and cytotoxic effects in these
cells, with IC50 values of 15 and 20 íM, toward HeLa
and HSC-3, respectively (Table 1). Both chelates exhib-
ited an irreversible effect. This is in agreement with our
previous study on the antineoplastic effect of compounds
II and III on HeLa cells,31 which demonstrated the
(presently confirmed) high antitumor activity of III
against this type of cancer line (IC50 ) 5 íM). Also,
chelate II yielded an IC50 of 13 íM against HeLa cells
and of 20 íM for the HSC-3 line (Table 1).
It thus seems that the number of metal centers within
the drug determines its antiproliferative and cytotoxic
activity, which was found, for the cell lines tested, to
increase with the number of Pt(II) ions coordinated to
the amine ligand(s) (III vs II and IV; Figure 1, Table
1). The degree of flexibility of the chelate also appears
to be important, as well as the orientation of its DNA
potential binding sites (either cis or trans relative to
the polyamine(s) backbone), a higher flexibility, and a
cis localization of the cisplatin-like groups within the
complex corresponding to a more effective agent (II vs
IV; Figure 1, Table 1). Furthermore, the results ob-
tained for leukemia nonadherent cells and epithelial-
like adherent cells reflect a specificity of complex III
toward the latter, a quite small antiproliferative and
cytotoxic activity being measured for THP-1, MOLT-3,
and CCRF-CEM cells, even after prolonged drug expo-
sure (Table 1, Figures 2 and 3), while for HeLa and
HSC-3 cells an evident cytotoxicity was observed at
early times of drug incubation. Figure 4 illustrates the
cytotoxic behavior of chelate III against HeLa cells
compared to that toward THP-1 and MOLT-3 lines.
In contrast, the macrocyclic-like complexes V-VII
were found to display a clear specificity as antiprolif-
erative and cytotoxic agents toward the leukemia cell
lines (Table 1, Figures 2, 3, and 5). Moreover, in most
of the cancer cells tested, compound V was shown to be
more effective than its analogues VI and VII, which is
most probably a consequence of its higher flexibility,
since the length of the (CH2)n chains between Pt(II)
centers decreases from V to VII (Figure 1).
The degree of reversibility of both the antiproliferative
and cytotoxic effects displayed by compounds aimed for
use as antitumor drugs is, understandably, of the
utmost importance. In fact, consideration of a recovery
period following drug exposure, apart from allowing the
determination of the reversibility of the drug effect, as
well as the measurement of a possible delayed cytotox-
icity, avoids over- or underestimation of the level of cell
killing achieved. The present results indicate that the
antiproliferative and cytotoxic activities of complex III
Figure 4. Time dependence of the cytotoxic effect of com-
pound III (100 íM) toward HeLa, THP-1, and MOLT-3 cell
lines. The cells (3  105 cells/mL) were incubated with the
drugs for periods of 24-72 h. Every 24 h, aliquots of the cell
suspensions were removed and cell viability was evaluated by
the Alamar blue colorimetric assay (as described in the
Experimental Section). In addition, the drug was removed 72
h after seeding and the cell viability was assessed following a
further incubation of 72 h. The data are expressed as a
percentage of the control Alamar reduction (100%) and rep-
resent the average ( mean standard deviation from experi-
ments carried out in triplicate. For intergroup comparison, p
< 0.01.
Figure 5. Time dependence of the cytotoxic effect of compounds V (A) and VII (B) (100 íM) toward HeLa, THP-1, and MOLT-3
cell lines. The cells (3  105 cells/mL) were incubated with the drugs for periods of 24-72 h. Every 24 h, aliquots of the cell
suspensions were removed and cell viability was evaluated by the Alamar blue colorimetric assay (as described in the Experimental
Section). In addition, the drug was removed 72 h after seeding and the cell viability was assessed following a further incubation
of 72 h. The data are expressed as a percentage of the control Alamar reduction (100%) and represent the average ( mean
standard deviation from experiments carried out in triplicate. For intergroup comparison between the different compounds, p <
0.05. For intergroup comparison between cell lines, the asterisk (/) indicates p < 0.01.
Polynuclear Pt(II) Chelates Journal of Medicinal Chemistry, 2004, Vol. 47, No. 11 2921
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are irreversible for all epithelial cell lines tested for
concentrations higher than 50 íM, as opposed to the
leukemia cells (Figures 2-4). Also, chelate IV displayed
irreversible anticancer properties against HeLa and
HSC-3 lines (for concentrations equal to or higher than
50 íM). However, while its cytotoxic effect was found
to be reversible toward THP-1 and MOLT-3 leukemia
cells (Figure 3), its growth-inhibition properties were
shown to be irreversible for these cells (Figure 2). In
turn, compound II presented a reversible effect against
both HeLa and MOLT-3 cells, even at 100 íM (this
factor having not been assessed in a previously reported
work on the cytotoxic activity of II8). Chelates V-VII,
at both 75 íM (data not shown) and 100 íM concentra-
tions, displayed an irreversible antitumor effect against
THP-1 and MOLT-3 lines (Figures 2, 3, and 5).
A significant disavantage of the presently used che-
motherapeutic agents is their rather high toxicity,
mainly due to side reactions with other biomolecules
apart from DNA (e.g., proteins). To evaluate this factor
for the complexes now investigated, cytotoxicity experi-
ments were carried out in non-neoplastic cells (human
embryonic fibroblasts from lung tissue (L-132 cell line)).
The results obtained allowed us to conclude that all the
chelates studied present quite a low toxicity against
healthy cells (Table 1). Complex V displayed the higher
cytotoxic effect toward noncancer cells (IC50 ) 50 íM),
which was, however, found to be almost totally reversed
upon drug removal (Figure 3).
Farrell and co-workers have recently reported the
synthesis and antitumor properties of several dinuclear
Pt(II) complexes with bridging diamine linkers of vary-
ing chain lengths,24,30 displaying high activity both in
vitro and in vivo even against cisplatin-resistant cancer
cell lines. These compounds, containing two PtCl(NH3)2
or PtCl2(NH3) moieties linked by polyamine groups in
a cis orientation, can be compared to complex IV
presently studied, which comprises two cisplatin-like
PtCl2(NH)(NH2) fragments in a trans conformation
instead. The IC50 values reported by Farrell for those
dinuclear chelates against leukemia cell lines are lower
than 1 íM, as opposed to the very high values now
obtained for lines THP-1, MOLT-3, and CCRF-CEM
cells (Table 1). As previously referred to above, the trans
position of the Cl leaving groups relative to the amine
backbone and the lower flexibility of complex IV relative
to the ones studied by Farrell’s group are probably
responsible for a significant decrease of the correspond-
ing antitumor activity. The effect of the degree of
flexibility of the compounds tested as anticancer drugs
is clearly reflected in the results presently obtained for
compound III (IC50 value toward HeLa cells equal to 5
íM (Table 1)) when compared to the ones reported for
the cationic trinuclear Pt(II) chelate BBR3464 (a bi-
functional (1,0,1/ttt) type complex of formula [Pt(NH3)2]3-
[H2N(CH2)6NH2]2Cl2), which displays a higher (and
equally irreversible) cytotoxic potency in similar types
of cancer cells (e.g., 0.012 íM against the A2780 ovarian
carcinoma line).16,17,19,29,30
Summary and Conclusions
The time- and dose-dependent growth-inhibition and
cytotoxic effects determined for the distinct Pt(II)
complexes presently tested against the human epithel
ial-type and leukemia cancer cell lines HeLa, HSC-3,
THP-1, MOLT-3, and CCRF-CEM, as well as toward the
L-132 noncancer cells, allowed us to gain a better insight
into the structure-activity relationships governing this
antitumor activity.
Some of the chelates studied were found to behave
as rather efficient antiproliferative and cytotoxic agents,
their effect on healthy cells being reversible upon drug
removal. Complexes II-IV revealed a distinct specificity
toward adherent cancer cells, while V-VII exhibited
this behavior against leukemia cells. In fact, complex
III was particularly effective on HeLa cells (corroborat-
ing previously reported results31), as well as against the
HSC-3 cancer cell line.
From the results now obtained, it is possible to
conclude that the conformational preferences of the
complexes studied (under physiological conditions),
namely, the nature of the amine ligand(s) (e.g., the
number of N atoms), the characteristics of the leaving
groups at platinum (chlorine atoms in the compounds
now tested), the number and coordination mode of the
metal ion(s), and their chemical environment (which
basically contains a di- or triamine and a mono- or
dichloro moieties), determine their antitumor activity,
most probably through induction of DNA structural
rearrangements. Thus, the design of new, more effective
anticancer drugs should be governed by these crucial
factors, since slight changes in either the polyamine
conformation or the metal coordination are sufficient to
significantly change the in vitro antiproliferative and/
or cytotoxic properties of these kinds of compounds.
Furthermore, some relevant criteria for future, third-
generation Pt(II) drugs should also be considered,
namely, good water solubility, stability under physi-
ological conditions, absence of undesired reactions, and
optimized hydrolysis reactions within the cell. Tissue
specificity and low toxicity toward healthy cells are also
goals expected to be achieved in the near future.
Experimental Section
Chemicals. Culture media (DMEM-HG and RPMI-1640),
antibiotics (penicillin-streptomycin 100 solution), carbopl-
atin, cisplatin, EDTA (ethylenediaminetetraacetic acid, diso-
dium salt, dihydrate), glutamine, HEPES, MTT, phenol red
(phenolsulfonphthalein), isopropyl alcohol, Trypan blue (0.4%
solution, prepared in 0.81% sodium chloride and 0.06% dibasic
potassium phosphate), trypsin, trisodium citrate, inorganic
salts, and acids (of analytical grade) were purchased from
Sigma-Aldrich Chemical Co. (Madrid, Spain). Fetal calf serum
was obtained from Biochrom KG, Berlin. Alamar blue was
acquired from Accurate Chemical & Scientific Corporation,
Westbury, NY.
Cells. The following human cell lines were used: epithelial-
like adherent cell linesshuman cervix adenocarcinoma (HeLa)
and squamous tongue epithelioma (HSC-3); leukemias
lymphoblastic leukemia (CCRF-CEM), acute lymphoblastic
leukemia (MOLT-3), and acute monocytic leukemia (THP-1);
fibroblasts from embryonic lung tissuesL-132. HeLa, THP-1,
and MOLT-3 were purchased from the European Collection
of Cell Cultures (ECACC, U.K.). HSC-3 and CCRF-CEM were
obtained from the American Type Culture Collection (ATCC),
MD. L-132 was kindly offered by the Centre of Experimental
Medicine and Surgery of the University General Hospital
Gregorio Maran˜on, Madrid, Spain.
Physical Measurements. Synthesized compounds were
identified by FTIR spectroscopy. Spectra were recorded on an
ATI Mattson Genesis series FTIR spectrometer, using potas-
sium bromide disks. The elemental analysis of the complexes
2922 Journal of Medicinal Chemistry, 2004, Vol. 47, No. 11 Teixeira et al.
D
ow
nl
oa
de
d 
by
 P
O
RT
U
G
A
L 
CO
N
SO
RT
IA
 M
A
ST
ER
 o
n 
Ju
ly
 1
0,
 2
00
9
Pu
bl
ish
ed
 o
n 
A
pr
il 
22
, 2
00
4 
on
 h
ttp
://
pu
bs
.a
cs
.o
rg
 | d
oi:
 10
.10
21/
jm
031
123
8
were carried out at the Microanalysis Laboratory, Chemistry
Department, University of Manchester and at the Butterworth
Laboratory, Middlesex, U.K.
Synthesis. The Pt(II) complexes studied in this work were
the following: (H3spd)2(PtCl4)3 (I), [PtCl2(Hspd)]2(PtCl4)] (II),
(PtCl2)3(spd)2 (III), (PtCl2)2(sp) (IV), [PtCl(spd)]2(PtCl4) (V),
[PtCl(NH2(CH2)3NH(CH2)3NH2)]2(PtCl4) (VI), and [PtCl-
(NH2(CH2)2NH(CH2)2NH2)]2(PtCl4) (VII) (Figure 1) (spd )
spermidine, NH2(CH2)3NH(CH2)4NH2; sp ) spermine, NH2-
(CH2)3NH(CH2)4NH(CH2)3NH2). They were synthesized either
according to reported methods (I, II, III,8 IV, V, and VII41) or
following experimental procedures developed in our laboratory
(complex VI). In a 100 mL round-bottom flask, K2PtCl4 (1.00
g, 2.41 mmol) was dissolved in water (30 mL), and to this
solution dipropylenetriamine (1.29 mL, 9.20 mmol) was added.
The pH of the solution was adjusted to ca. 3 by the addition of
1 M HCl, which was followed by further refluxing for 6 h. The
red solution was filtered, concentrated to 4 mL, and left
overnight in a refrigerator. The crystals were removed by
filtration, washed with ethanol, and dried under vacuum.
Recrystallization of this product in a small amount of water
afforded red-orange crystals (0.127 g, 0.32 mmol), which were
dissolved in water (3 mL). This solution was added under
continuous stirring to a solution of K2PtCl4 (0.06 g, 0.16 mmol)
in water (5 mL). A white-brown precipitate formed almost
immediately after mixing. The mixture was stirred at room
temperature for 36 h. The pure complex was collected by
filtration, washed with water and diethyl ether, and finally
vacuum-dried for 2 days (0.055 g, 32.5% yield). Anal. (Pt3C14-
Cl12H44N6) (I) C, H, N, Cl. Anal. (Pt3C14Cl8H40N6) (II) C, H, N,
Cl. Anal. (Pt3C14Cl6H38N6) (III) C, H, N, Cl. Anal. (Pt2C10-
Cl4H26N4) (IV) C, H, N, Cl. Anal. (Pt3C14Cl6H38N6) (V) C, H,
N, Cl. Anal. (Pt3C12Cl6H34N6) (VI) C, H, N, Cl. Anal. (Pt3C8-
Cl6H26N6) (VII) C, H, N, Cl.
Preparation of Solutions. All compounds studied were
water-soluble. Solutions were prepared at concentrations
ranging from 5.0  10-5 to 1.5  10-4 M in phosphate-buffered
saline solution (PBS): 132.0  10-3 M NaCl, 4.0  10-3 M
KCl, 1.2  10-3 M NaH2PO4, 1.4  10-3 M MgCl2, 6.0  10-3
M glucose, 1.0  10-2 M HEPES (N-[2-hydroxyethyl]pipera-
zine-N′-[4-butanesulfonic acid]). Trypan blue was used as a
0.04% (w/v) solution in PBS. MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide) was prepared at a con-
centration of 0.5 mg/mL in PBS solution containing 1.0  10-3
M CaCl2.
Biological Assays. Cell Culture. Stock cultures of cells
were maintained at 37 °C under 5% CO2. HeLa, HSC-3, and
L-132 cells (grown in monolayers) were kept in Dulbecco’s
modified Eagle’s high glucose (4500 mg/L) medium (DMEM-
HG) supplemented with 10% heat-inactivated fetal calf serum,
glutamine (1.168 g/L), and antibiotics (100 units of penicillin
and 100 mg of streptomycin). THP-1, MOLT-3, and CCRF-
CEM cells were cultured as a suspension in Roswell Park
Memorial Institute medium (RPMI-1640), containing 25 mM
HEPES and 25 mM sodium bicarbonate supplemented with
10% heat-inactivated fetal calf serum, glutamine (0.3 g/L), and
antibiotics (100 units of penicillin and 100 mg of streptomycin).
The cell lines were subcultured twice a week. HeLa cells
were harvested using a dissociation medium composed of 136.9
 10-3 M NaCl, 2.7  10-3 M KCl, 8.2  10-3 M Na2HPO4, 1.5
 10-3 M KH2PO4, 4.0  10-4 M EDTA (pH 7.4) and containing
0.0004% (w/v) phenol red. HSC-3 and L-132 cells were
harvested upon addition of trypsin/EDTA (0.05% trypsin, 0.35
mM EDTAâ4Na reconstituted in free Ca2+ and Mg2+ balanced
salt solution).
Toxicity and Cell Growth Inhibition Evaluation. Cy-
totoxicity and cell density evaluation following drug exposure
(for drug concentrations ranging from 5 to 150 íM) were
assessed with use of standard assays. Cells were plated at 3
 105 cells/mL on 12-well dishes. At 24 h hours after seeding,
drug solutions were added to the medium and the cultures
were incubated at 37 °C. Cells were harvested and analyzed
(both in controls and in drug-treated cultures) every 24 h for
a total period of 3-5 days (depending on the cell line and the
compound used). Reversibility of the drug effect was tested
by removing the drug and adding fresh culture medium in the
last day of incubation with the drug and assessing the cell
viability following 3 more days of incubation. Cell density and
viability were determined by Trypan blue exclusion on single-
cell suspensions obtained from the monolayer cultures. Cell
viability was further assessed by both mitochondrial dehydro-
genase activity (MTT assay) and the Alamar blue colorimetric
test. All experiments were performed in triplicate.
The MTT assay for cell injury is based on the ability of
mitochondrial dehydrogenases of viable cells to reduce MTT
to a purple formazan product (insoluble in water)42 that can
be quantified spectrophotometrically43,44 (after solubilization
in isopropyl alcohol containing 40 mM HCl). For each time
point, the culture medium was aspirated and 1 mL of MTT
solution (5 mg/mL in PBS) was added to the cells (both control
and drug-treated cells) followed by a 4 h incubation at 37 °C.
After this period, the formazan crystals formed were dissolved
upon addition of 1 mL of 0.04 M HCl in 2-propanol and the
absorbance of these solutions was measured at 570 nm
(against a blank containing MTT and HCl/2-propanol in a 1:1
ratio). The results were expressed as the percentage of MTT
reduction, setting the absorbance of control cells as 100%.
The Alamar blue assay is a fluorimetric/colorimetric test
based on the detection of metabolic activity.45 It incorporates
an oxidation-reduction indicator that changes from the
oxidized form (nonfluorescent, blue) to the reduced state
(fluorescent, red) in response to chemical reduction of growth
medium, as a result of cell growth. For each time point, Alamar
blue was added to the cells (both control and drug-treated)
and to culture medium (blank) in an amount equal to 10% of
the total culture volume. The samples were incubated for 8 h
at 37 °C, and the absorbance was then measured at both 570
nm (Aì1, A′ì1) and 600 nm (Aì2, A′ì2) (against the blank). Cell
viability was expressed as a percentage of the nontreated
control cells and was calculated according to the following
equation:
ox and RED represent the molar absorptivity coeficients of the
oxidized and reduced forms of Alamar blue, respectively, at
570 and 600 nm: (ox)ì1 ) 80.856, (RED)ì1 ) 155.677, (ox)ì2 )
117.216, and (RED)ì2 ) 14.652.
The 50% inhibitory concentration (concentration of drug
required to inhibit cell growth by 50%, IC50) was calculated
for each drug tested from dose-response curves (for incubation
periods of both 48 and 72 h).
All the results presented were obtained by three indepen-
dent methods: cell density measurement with Trypan blue
exclusion method and cell viability assessment with MTT and
Alamar blue colorimetric assays.
Statistical Analysis. All experiments were performed in
triplicate. The results are expressed as mean values ( SD (the
corresponding error bars being displayed in the graphical
plots). Statistical analyses were performed using ANOVA,
followed by a post hoc test of Fisher’s protected least significant
difference. Statistical comparison between the data was based
on the Pearson correlation coefficient, values less than 0.05
being considered as significant.
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